glimepiride has been researched along with Metabolic Syndrome in 10 studies
glimepiride: structure given in first source
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 9.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "This study compared the effects of pioglitazone or rosiglitazone added to glimepiride on a range of lipid parameters, focusing on Lp(a) and Hcy, in patients with type 2 diabetes mellitus and the metabolic syndrome." | 9.12 | Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006) |
| "The aim of this study was to assess the differential effect on glucose and lipid variables and tolerability of the combination of glimepiride plus pioglitazone or rosiglitazone in patients with type 2 diabetes mellitus (DM) and metabolic syndrome." | 9.11 | Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD, 2004) |
| "To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome." | 9.11 | Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005) |
| "To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters." | 9.11 | A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S, 2005) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 9.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 5.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "This study compared the effects of pioglitazone or rosiglitazone added to glimepiride on a range of lipid parameters, focusing on Lp(a) and Hcy, in patients with type 2 diabetes mellitus and the metabolic syndrome." | 5.12 | Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006) |
| "The aim of this study was to assess the differential effect on glucose and lipid variables and tolerability of the combination of glimepiride plus pioglitazone or rosiglitazone in patients with type 2 diabetes mellitus (DM) and metabolic syndrome." | 5.11 | Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD, 2004) |
| "To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome." | 5.11 | Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005) |
| "To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters." | 5.11 | A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S, 2005) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 5.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farooq, R | 1 |
| Amin, S | 1 |
| Hayat Bhat, M | 1 |
| Malik, R | 1 |
| Wani, HA | 1 |
| Majid, S | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Gropler, RJ | 1 |
| Derosa, G | 5 |
| Cicero, AF | 5 |
| Gaddi, A | 3 |
| Ragonesi, PD | 3 |
| Fogari, E | 3 |
| Bertone, G | 1 |
| Ciccarelli, L | 5 |
| Piccinni, MN | 5 |
| Kalyoncu, NI | 1 |
| Yaris, F | 1 |
| Kadioglu, M | 1 |
| Kesim, M | 1 |
| Ulku, C | 1 |
| Yaris, E | 1 |
| Unsal, M | 1 |
| Dikici, M | 1 |
| Gaddi, AV | 2 |
| Salvadeo, S | 3 |
| Peros, E | 1 |
| Ghelfi, M | 2 |
| Ferrari, I | 3 |
| Fogari, R | 2 |
| Pricolo, F | 2 |
| Koshiba, K | 1 |
| Nomura, M | 1 |
| Nakaya, Y | 1 |
| Ito, S | 1 |
| D'Angelo, A | 1 |
| Salvadeo, SA | 1 |
| Gravina, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for glimepiride and Metabolic Syndrome
3 other studies available for glimepiride and Metabolic Syndrome
| Article | Year |
|---|---|
Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs.
Topics: Adiponectin; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Leptin; Male; Me | 2017 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Obesity Agents; Female; Humans; Hypoglycemic A | 2005 |